Athernal Bio Launches with £3.5 Million Funding from Delin Ventures
Cambridge, UK, October 1, 2025 – Athernal Bio today announced its official launch alongside £3.5 million funding from founding investor Delin Ventures. The company is focused on the development of targeted immunotherapies for high-risk clonal haematopoiesis (CH), a widespread cancer precursor condition which can lead to acute myeloid leukaemia (AML) and other haematological cancers. This […]